Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -101K | 0 | 0 | 0 | 0 |
| Operating Income | -16M | -10M | -9M | -9M | -6M |
| EBITDA | -16M | -9M | -9M | -9M | -20M |
| Net Income | -15.8B | -9M | -9M | -9M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.65
+0.65% today
1Y Change
-46.15%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Quoin Pharmaceuticals, Ltd. (QNRX) is a Healthcare stock with listed on NASDAQ. The stock last traded around $4.65 and down 46.2% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -22033.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -22033.5%, free cash flow -172236.3% with operating margin 0.0% and ROIC -110.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines QNRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QNRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QNRX Max Drawdown
-81.17%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QNRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$21.5M
-128.8% YoY
Free Cash Flow
-$6.3M
+27.3% YoY
Revenue Growth
+0.0%
EPS Growth
-22033.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -101K | 0 | 0 | 0 | 0 |
| Operating Income | -16M | -10M | -9M | -9M | -6M |
| EBITDA | -16M | -9M | -9M | -9M | -20M |
| Net Income | -15.8B | -9M | -9M | -9M | -21M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3.8B | 4M | 2M | 3M | 7M |
| Total Assets | 20M | 16M | 12M | 14M | 9M |
| Total Liabilities | 7M | 7M | 7M | 7M | 9M |
| Shareholder Equity | 13M | 9M | 6M | 7M | 657K |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -3.8B | -4M | -2M | -3M | -7M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+32.6% YoY
Capital Expenditures
625K
-150.0% YoY
Free Cash Flow
6M
+27.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-310165.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.